# FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Source: https://onco.cc/trials/nct06733038/  
OnCo record `nct06733038` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of atezolizumab, bevacizumab (glioblastoma use), fOLFIRI (5-FU, leucovorin, irinotecan), fOLFOX (5-FU, leucovorin, oxaliplatin) and other drugs in colorectal cancer, run by Gruppo Oncologico del Nord-Ovest, now recruiting.

## Summary

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. is a phase 3, randomised interventional study registered as NCT06733038 by Gruppo Oncologico del Nord-Ovest, with a registry enrolment figure of 238 participants, started 2024-11-15 and due to reach its primary completion in 2028-04-01. Interventions recorded: Atezolizumab; Bevacizumab; Irinotecan (CPT-11); Oxaliplatin; Leucovorin; Fluorouracil (5-FU). Conditions listed: Colorectal Cancer. Primary outcome: Progression Free Survival (PFS). Colorectal eligibility wording from the registry: "* Histologically proven diagnosis of colorectal cancer;". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: AtezoTRIBE2
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06733038
- Phase: 3
- Setting: Phase III Randomized Study of FOLFOXIRI Plus Bevacizumab and Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-Line Treatment of Unresectable pMMR and Immunoscore IC-High Metastatic Colorectal Cancer Patients
- Sponsor: Gruppo Oncologico del Nord-Ovest
- Enrolled: 238

## Sources

- ClinicalTrials.gov NCT06733038: https://clinicaltrials.gov/study/NCT06733038

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06733038.json